DENVER, Colo., Dec 30, 2024 (247marketnews.com)- Notable listings on the penultimate day of 2024 include Xeriant (OTCQB: XERI), Nxu (NASDAQ: NXU), Intrusion (NASDAQ: INTZ), MicroCloud Hologram (NASDAQ: HOLO), Faraday Future (NASDAQ: FFIE), NLS Pharmaceutics (NASDAQ: NLSP), and Autonomix Medical (NASDAQ: AMIX).
Xeriant (OTCQB: XERI) published a holiday message stating that Xeriant made significant progress with the development of its NEXBOARD composite building panel, made primarily from recycled plastic and fiber waste, and that the product is well-positioned for some major wins in 2025.
Xeriant further stated that it expects to announce “some exciting aerospace announcements during the first quarter of 2025.”
Nxu (NASDAQ: NXU) is experiencing its best trading day since filing a Form S-4 for its proposed Business Combination with Verde Bioresins, a leader in sustainable product innovation and full-service bioplastics production, last month.
The deal was originally announced on October 2024 and calls for Nxu to acquire all of the issued and outstanding common shares of Verde in an all-stock transaction, with the combined company expected to be renamed Verde Bioresins and list its common stock on Nasdaq under the new ticker symbol “VRDE”.
Intrusion (NASDAQ: INTZ) set a new 52-week high of $7.34, easily besting its January and February trading levels by more than $2.
MicroCloud Hologram (NASDAQ: HOLO) reportedly developed a fast adiabatic driving protocol to achieve coherent control of two heavy hole spin qubits in a double quantum dot (QD) system.
The Company’s announcement stated, “The fast adiabatic driving protocol is essentially a precise energy control paradigm based on the quantum adiabatic theorem. In the context of a complex double quantum dot (QD) system, it carefully designs control paths according to the system’s adiabatic evolution rules, guiding the two heavy hole spin qubits along predefined trajectories with high-precision quantum state fidelity to achieve state transitions. This approach cleverly avoids the risk of quantum state distortions caused by abrupt energy changes or external disturbances. Similar to the precise navigation in interstellar travel, this control mode ensures accurate quantum state transitions by meticulously managing the energy variations in the quantum system, thereby achieving higher quantum state fidelity compared to traditional protocols.
“From the perspective of practical application efficiency, the implementation of fast quasi-adiabatic driving through spin-orbit coupling mechanisms results in two significant technological outcomes. On one hand, charge noise in the qubit operation process is deeply suppressed. Charge noise has long been a troublesome issue in the field of quantum control, acting like an “invisible interference factor” hidden in the microscopic world. It disturbs the stable state of qubits with subtle and continuous fluctuations, frequently causing computational errors. HOLO’s innovative technological approach serves as a solid “electromagnetic shielding barrier” for qubits, optimizing the electrical environment of the quantum system to effectively block the infiltration of charge noise, ensuring that qubits operate stably in a relatively “low-noise” environment. On the other hand, it achieves high stability in qubit initialization. As the crucial starting point for quantum computation, the stability of initialization plays a decisive role in the accuracy of subsequent full-round computations. High stability means that even when facing external uncertainties such as temperature fluctuations and weak electromagnetic interference, qubits can consistently return to their initial set state with precision, laying a solid foundation for performing high-complexity and high-precision quantum computing tasks.”
Faraday Future Intelligent Electric (NASDAQ: FFIE) stated that it will deliver its first FF 91 2.0 Futurist Alliance, for 2025, to Luke Hans, a prominent entrepreneur and leader in the Los Angeles Chinese community, in January, during a delivery ceremony with FF executives.
NLS Pharmaceutics (NASDAQ: NLSP) and Kadimastem reported that NLS filed a Form F-4 Registration Statement with the Securities and Exchange Commission regarding their previously announced merger move.
Ronen Twito, Kadimastem’s Chairman of the Board and CEO, commented, “We are making significant strides toward achieving our strategic objectives at Kadimastem. The submission of NLS’s Registration Statement related to the merger with the SEC marks a crucial milestone in our journey to conclude the merger. We believe the pending merger will empower us to further unlock the potential of our innovative technologies. Our commitment remains steadfast in delivering value to our shareholders while making a meaningful impact in the field of cell therapy.”
Alex Zwyer, Chief Executive Officer of NLS, stated, “We are excited about the momentum building around the merger. We believe that this strategic partnership is set to strengthen our market position and enhance shareholder value through expanded growth opportunities. We are focused on executing the merger effectively, as we move forward together in the biotechnology sector.”
Autonomix Medical (NASDAQ: AMIX) stated that the United States Patent and Trademark Office (USPTO) issued U.S. patent 12,064,256 (‘256 patent) titled, Systems and Methods for Treating Cancer and/or Augmenting Organ Function, to the Company, covering technology including, but not limited to, systems, methods and devices for interventionally treating cancerous tumors and cancer related pain, which Autonomix is initially advancing the development of its technology to address pancreatic cancer-related pain.
Brad Hauser, CEO of Autonomix, commented, “As we continue to advance the development of this potentially groundbreaking technology, bolstering our patent protection remains a key priority.
“Supported by recent positive preclinical results demonstrated to date, we believe the depth and breadth of our proprietary technology provides the opportunity for further evaluation and we intend to explore its potential to reduce cancer progression and metastases.”
Autonomix’s catheter-based sensing technology is covered by over 80 issued patents and over 40 pending patent applications, globally.
The post Nearly There appeared first on 24/7 MarketNews.
